ELND 007 (Compound 34) is a metabolically stable gamma-secretase inhibitor designed to selectively inhibit amyloid beta (Abeta) generation while minimizing Notch inhibition. Developed alongside ELND 006 (Compound 30), it underwent human clinical trials following a synthetic strategy emphasizing diversity and chirality. In preclinical studies, ELND 007 showed promising in vitro and in vivo characteristics, effectively reducing Abeta levels. Comparative studies with other gamma-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat highlighted its efficacy in lowering Abeta production, particularly demonstrated by reduced Abeta levels in the cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic benefit for Alzheimers disease[1].
Molecular Weight:
438.40
CAS Number:
[1444006-79-4]
Formula:
C19H14F4N4O2S
Target:
Amyloid-beta,gamma-secretase
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
